PFE and AMGN Related Headlines
Go Back- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- The Next Generation of the GLP-1 Revolution Is Already Underway
- FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
- Barclays launches U.S. biopharma coverage with four preferred picks
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
PFE and AMGN Related Press Releases
Go Back- The Next Generation of the GLP-1 Revolution Is Already Underway
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
